ROCKVILLE, Md. and SUZHOU, China, July 2, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic,…
Month: July 2023
EL SEGUNDO, Calif., July 2, 2023 /PRNewswire/ — The nation’s largest local broadcaster, Nexstar Media Group, is forcing the temporary loss of more than 200 stations for DIRECTV, DIRECTV STREAM and U-verse customers in more than 100 metro areas following the recent contract expiration….
LOS ANGELES, July 2, 2023 /PRNewswire/ — Platinum Equity announced today that the acquisition of the JELD-WEN Australasia windows, doors and related building products business from JELD-WEN Holding, Inc. for approximately $461 million has been completed. “We are pleased to have provided…
CHARLOTTE, N.C., July 2, 2023 /PRNewswire/ — JELD-WEN Holding, Inc. (NYSE: JELD), a leading global manufacturer of building products, today announced that it has completed the previously announced sale of its Australasia business to Platinum Equity, a global investment firm. “The closing…
XANGAI, 2 de julho de 2023 /PRNewswire/ — A Bioheart (02185.HK), juntamente com sua subsidiária holding Angiocare, anuncia o resultado clínico do Iberis-HTN na China Interventional Therapeutics 2023. O Iberis-HTN é um estudo clínico prospectivo, multicêntrico, cego e randomizado para…
SHANGHÁI, 2 de julio de 2023 /PRNewswire/ — Bioheart (02185.HK), junto con su filial Angiocare anuncia el resultado clínico de Iberis-HTN en China Interventional Therapeutics 2023. Iberis-HTN es un ensayo prospectivo, multicéntrico, ciego, aleatorizado y controlado para evaluar la…
SHANGHAI, 2 juillet 2023 /PRNewswire/ — Bioheart (02185.HK) et sa filiale Angiocare annoncent les résultats cliniques d’Iberis-HTN lors du salon China Interventional Therapeutics 2023. Iberis-HTN est un essai prospectif, multicentrique, randomisé, contrôlé et mené en aveugle, visant à…